Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1982 3
1983 1
1984 1
1985 1
1986 2
1987 2
1988 7
1989 5
1990 12
1991 4
1992 12
1993 9
1994 19
1995 16
1996 22
1997 16
1998 27
1999 36
2000 38
2001 30
2002 35
2003 51
2004 70
2005 82
2006 99
2007 112
2008 130
2009 137
2010 170
2011 224
2012 243
2013 288
2014 368
2015 383
2016 438
2017 502
2018 530
2019 584
2020 748
2021 847
2022 579
Text availability
Article attribute
Article type
Publication date

Search Results

6,215 results
Results by year
Filters applied: . Clear all
Page 1
Leucine-tRNA-synthase-2-expressing B cells contribute to colorectal cancer immunoevasion.
Wang Z, Lu Z, Lin S, Xia J, Zhong Z, Xie Z, Xing Y, Qie J, Jiao M, Li Y, Wen H, Zhao P, Zhang D, Zhou P, Qian J, Luo F, Wang L, Yu H, Liu J, Gu J, Liu R, Chu Y. Wang Z, et al. Among authors: xia j. Immunity. 2022 Jun 14;55(6):1067-1081.e8. doi: 10.1016/j.immuni.2022.04.017. Epub 2022 Jun 3. Immunity. 2022. PMID: 35659337
Large-scale multiplexed mosaic CRISPR perturbation in the whole organism.
Liu B, Jing Z, Zhang X, Chen Y, Mao S, Kaundal R, Zou Y, Wei G, Zang Y, Wang X, Lin W, Di M, Sun Y, Chen Q, Li Y, Xia J, Sun J, Lin CP, Huang X, Chi T. Liu B, et al. Among authors: xia j. Cell. 2022 Aug 4;185(16):3008-3024.e16. doi: 10.1016/j.cell.2022.06.039. Epub 2022 Jul 22. Cell. 2022. PMID: 35870449
Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated NSCLC.
Wang XS, Bai YF, Verma V, Yu RL, Tian W, Ao R, Deng Y, Xia JL, Zhu XQ, Liu H, Pan HX, Yang L, He YK, Bai HS, Luo X, Guo Y, Zhou MX, Sun YM, Zhang ZC, Li SM, Cheng X, Tan BX, Han LF, Liu YY, Zhang K, Zeng FX, Jia L, Hao XB, Wang YY, Feng G, Xie K, Lu Y, Zeng M. Wang XS, et al. Among authors: xia jl. J Natl Cancer Inst. 2022 Jan 30:djac015. doi: 10.1093/jnci/djac015. Online ahead of print. J Natl Cancer Inst. 2022. PMID: 35094066
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.
Meng X, Wu T, Hong Y, Fan Q, Ren Z, Guo Y, Yang X, Shi P, Yang J, Yin X, Luo Z, Xia J, Zhou Y, Xu M, Liu E, Jiang G, Li S, Zhao F, Ma C, Ma C, Hou Z, Li J, Wang J, Wang F. Meng X, et al. Among authors: xia j. Lancet Gastroenterol Hepatol. 2022 Mar;7(3):245-253. doi: 10.1016/S2468-1253(21)00378-2. Epub 2022 Jan 6. Lancet Gastroenterol Hepatol. 2022. PMID: 34998471 Clinical Trial.
Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.
Wang Y, Cao J, Gu W, Shi M, Lan J, Yan Z, Jin L, Xia J, Ma S, Liu Y, Li H, Pan B, Chen W, Fei X, Wang C, Xie X, Yu L, Wang G, Li H, Jing G, Cheng H, Zhu F, Sun H, Sang W, Li D, Li Z, Zheng J, Xu K. Wang Y, et al. Among authors: xia j. J Clin Oncol. 2022 Jul 10;40(20):2246-2256. doi: 10.1200/JCO.21.01676. Epub 2022 Mar 25. J Clin Oncol. 2022. PMID: 35333600 Clinical Trial.
Antibacterial Photodynamic Gold Nanoparticles for Skin Infection.
Qiu L, Wang C, Lan M, Guo Q, Du X, Zhou S, Cui P, Hong T, Jiang P, Wang J, Xia J. Qiu L, et al. Among authors: xia j. ACS Appl Bio Mater. 2021 Apr 19;4(4):3124-3132. doi: 10.1021/acsabm.0c01505. Epub 2021 Mar 19. ACS Appl Bio Mater. 2021. PMID: 35014400
6,215 results